Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG. Thompson AM, et al. Among authors: ferraldeschi r. Breast Cancer Res Treat. 2011 Jan;125(1):279-87. doi: 10.1007/s10549-010-1139-x. Epub 2010 Sep 1. Breast Cancer Res Treat. 2011. PMID: 20809362
Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen.
Ferraldeschi R, Howell SJ, Thompson AM, Newman WG. Ferraldeschi R, et al. J Clin Oncol. 2010 Oct 10;28(29):e584-5; author reply e586. doi: 10.1200/JCO.2010.30.1887. Epub 2010 Sep 7. J Clin Oncol. 2010. PMID: 20823421 No abstract available.
Lack of caveolin-1 (P132L) somatic mutations in breast cancer.
Ferraldeschi R, Latif A, Clarke RB, Spence K, Ashton G, O'Sullivan J, Evans DG, Howell A, Newman WG. Ferraldeschi R, et al. Breast Cancer Res Treat. 2012 Apr;132(3):1185-6. doi: 10.1007/s10549-012-1981-0. Epub 2012 Feb 7. Breast Cancer Res Treat. 2012. PMID: 22310961 No abstract available.
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium. Province MA, et al. Among authors: ferraldeschi r. Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23. Clin Pharmacol Ther. 2014. PMID: 24060820 Free PMC article.
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment.
Ferraldeschi R, Newman WG. Ferraldeschi R, et al. Pharmaceuticals (Basel). 2010 Apr 15;3(4):1122-1138. doi: 10.3390/ph3041122. Pharmaceuticals (Basel). 2010. PMID: 27713292 Free PMC article. Review.
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J. Ferraldeschi R, et al. Eur Urol. 2015 Apr;67(4):795-802. doi: 10.1016/j.eururo.2014.10.027. Epub 2014 Nov 4. Eur Urol. 2015. PMID: 25454616 Free PMC article.
63 results